<DOC>
	<DOC>NCT02346175</DOC>
	<brief_summary>The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.</brief_summary>
	<brief_title>Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>BMI:2035kg/m2; Medically stable based on physical examination, medical history, laboratory results, vital sign measurements, and 12lead electrocardiogram (ECG) at screening; On a stable regimen of antihyperglycemic therapy for at least 8 weeks prior to screening and had fasting plasma glucose (FPG) concentration lower than 13.9 mmol/L at baseline; Stable antihyperglycemic regimens could include a single oral agent (eg, metformin, a sulfonylurea, a thiazolidinediones ketone, a benzoic acid derivatives, a dipeptidyl peptidase4 inhibitor, or an Î±glucosidase inhibitor) with glycated hemoglobin (HbA1c) between 7.0% and 10.0%. History of clinically significant diabetic complications, type 1 diabetes mellitus, or repeated severe hypoglycemic episodes. Pregnancy or breastfeeding; Significant acute or chronic medical illness, including renal impairment, or recent surgery; Donation of blood or plasma within the 4 weeks prior to the start of the study;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>SHR3824 Type 2 diabetes mellitus SGLT2</keyword>
</DOC>